SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells 24,381 Shares

Key Points

• Chairman Jurgi Camblong sold 24,381 SOPHiA GENETICS shares at an average price of $6.29, generating $153,356.49. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced his ownership by 0.69% to 3.51 million shares.
• Camblong has made several additional sales since June, including 20,000 shares on July 21, bringing the disclosed recent sales to more than 150,000 shares.
• SOPHiA GENETICS shares recently traded at $5.58, while analysts maintain a consensus “Hold” rating with an average $9.00 price target. The company missed quarterly EPS expectations, though revenue exceeded estimates.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) Chairman Jurgi Camblong sold 24,381 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $6.29, for a total transaction of $153,356.49. Following the completion of the sale, the chairman directly owned 3,512,822 shares of the company's stock, valued at $22,095,650.38. This trade represents a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.63, for a total value of $132,600.00.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total value of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total value of $44,540.00.

SOPHiA GENETICS Price Performance

Shares of SOPHiA GENETICS stock traded down $0.07 during trading on Tuesday, hitting $5.58. 56,495 shares of the company's stock traded hands, compared to its average volume of 200,351. SOPHiA GENETICS SA has a twelve month low of $2.92 and a twelve month high of $6.77. The company has a market cap of $468.19 million, a PE ratio of -10.74 and a beta of 0.96. The firm's fifty day moving average price is $5.40 and its 200 day moving average price is $5.08. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The company had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million. Analysts forecast that SOPHiA GENETICS SA will post -0.58 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. BTIG Research reiterated a "buy" rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Finally, HC Wainwright assumed coverage on shares of SOPHiA GENETICS in a research note on Monday, July 20th. They issued a "buy" rating and a $12.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of "Hold" and an average price target of $9.00.

Institutional Trading of SOPHiA GENETICS

A number of large investors have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock worth $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC raised its holdings in SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock worth $11,529,000 after buying an additional 1,481,636 shares during the period. Hodges Capital Management Inc. acquired a new position in shares of SOPHiA GENETICS in the first quarter valued at approximately $2,157,000. Royce & Associates LP acquired a new stake in shares of SOPHiA GENETICS during the fourth quarter worth $2,009,000. Finally, Sei Investments Co. bought a new stake in shares of SOPHiA GENETICS in the first quarter valued at about $1,772,000. Institutional investors own 31.59% of the company's stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.